Real-World Comparison of Effectiveness, Treatment Persistence, and Safety of First-Line Advanced Therapies at 1 Year for Ulcerative Proctitis
Lay Summary In this retrospective cohort study, vedolizumab was associated with higher odds of steroid-free clinical remission at 1 year compared to anti-TNF agents for bio-naïve patients with ulcerative proctitis.
Authors
- Lindsay Clarke (ORCID: https://orcid.org/0009-0005-8088-5025)
- Rahul S. Dalal (ORCID: https://orcid.org/0000-0003-4622-8441)
- Jessica Ravikoff Allegretti (ORCID: https://orcid.org/0000-0003-3585-2425)
- Heidy Cabral
- Alex Carlin
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
Publication Details
- Journal
- Inflammatory Bowel Diseases
- Published
- 2024-09-19
- DOI
- https://doi.org/10.1093/ibd/izae215
- Citations
- 3
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.65